KDC-MN-374 – Kodiac biolabs

Plain-language summaryIntrigue 68 / 100

D-serine is the mirror-image form of the amino acid serine, and your brain makes it on purpose. It is the obligate co-agonist at the synaptic NMDA receptor, meaning the receptor will not open without it sitting in a dedicated pocket alongside glutamate. An enzyme called serine racemase builds it; another called DAAO breaks it down. Researchers have tested giving it as a drug to boost NMDA function in schizophrenia (where reduced NMDA signaling is implicated in negative and cognitive symptoms) and in depression. Phase 2 trials show small but real effects. The competing strategy is to inhibit DAAO so the brain keeps more of its own. The canonical NMDA glycine-site co-agonist for neuroscience research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

48/100

Canonical endogenous NMDA co-agonist; indispensable synaptic probe with modest clinical signal in schizophrenia

Yeah, D-serine isn’t a discovery compound or a clinical moonshot. It’s the obligatory co-agonist at synaptic NMDA receptors that your brain makes itself, and has been studied intensively since the late 1990s when Wolosker, Snyder and colleagues pinned serine racemase as the biosynthetic enzyme. On novelty, we’re not pretending this is fresh territory.

Here’s the thing: what makes D-serine interesting in 2026 isn’t novelty, it’s bench utility. If you’re running any NMDA receptor biology — LTP assays, synaptic plasticity models, glutamate hypothesis schizophrenia work — D-serine is the compound you reach for to saturate the glycine site at synaptic NMDARs. And that matters because D-serine and glycine are not interchangeable here: D-serine is the preferred endogenous co-agonist at synaptic NMDARs in cortex and hippocampus, while glycine hits extrasynaptic receptors preferentially. Use glycine where you should use D-serine, and you’re probing a different receptor population. That distinction is load-bearing in any serious NMDA-focused program.

The mechanism is genuinely elegant. Serine racemase converts L-serine to D-serine; D-amino acid oxidase (DAAO) degrades it. That serine racemase/DAAO regulatory axis is itself a research target — DAAO inhibitors like sodium benzoate and luvadaxistat (TAK-831) were developed precisely because they elevate endogenous D-serine levels without flooding the system with exogenous amino acid. The endogenous level story powers the schizophrenia hypothesis: reduced NMDA receptor function from insufficient D-serine availability is one of the more coherent mechanistic accounts of negative symptoms and cognitive deficits in that population.

On clinical evidence, the phase 2 trials exist. Heresco-Levy’s group and several others have run them. Effects on negative symptoms and cognitive function are real but modest — consistent direction, meaningful p-values in several trials, but not effect sizes that would get anyone excited at a clinical development meeting. It hasnt gone to phase 3. The DAAO inhibitor path is the more active clinical development vector right now, which makes exogenous D-serine administration somewhat less central as a therapeutic candidate and somewhat more of a reference tool.

What we like is the bench probe value. Any lab interrogating NMDA co-agonism, glycine-site pharmacology, or the serine racemase/DAAO axis needs D-serine in the toolkit. Sourcing is clean — high-purity free amino acid from major chemical suppliers, straightforward aqueous reconstitution, no solubility headaches. What we dont love is the clinical stall. A compound this tightly coupled to NMDA synaptic biology should anchor research programs, and it does — just not as a frontier target. It anchors them as the reference standard against which everything more novel gets measured.

Novelty: 28
Mechanism promise: 55
In-category differentiation: 55
Evidence quality: 52
Translational signal: 42
Research bench value: 65

Rationale D-serine’s D-stereoisomeric identity and specific serine racemase/DAAO biosynthetic axis distinguish it from generic L-serine or plain amino acids, so the basic-aa cap does not apply; scores are dragged down by low novelty (mature 1990s-2000s literature) and a stalled clinical development arc, but bench-value is meaningfully elevated as the canonical synaptic NMDA co-agonist that cannot simply be substituted with glycine in properly-designed NMDAR studies.

Endogenous NMDA receptor co-agonist

D-stereoisomer of serine; an endogenous obligatory co-agonist at the NMDA receptor glycine site.

Abstract

D-serine ((R)-2-amino-3-hydroxypropanoic acid; CAS 312-84-5; molecular formula C3H7NO3; molecular weight 105.09) is the D-stereoisomer of serine, an endogenous obligatory co-agonist at the glycine site of NMDA receptors. The compound is biosynthesized in the brain by serine racemase (the enzyme that converts L-serine to D-serine) and is metabolized by D-amino acid oxidase (DAAO). D-serine is the principal endogenous co-agonist for synaptic NMDA receptors in the cortex and hippocampus, while glycine itself co-agonizes extrasynaptic NMDA receptors. Pharmacologically, exogenous D-serine elevates NMDA receptor function, with research interest in schizophrenia (where reduced NMDA function is hypothesized as a contributor to negative symptoms and cognitive deficits) and depression (NMDA modulation as antidepressant target). Phase 2 trials in schizophrenia have shown small effects. Plasma half-life is approximately 4 hours; oral bioavailability is moderate. The DAAO inhibitor approach is an alternative to direct D-serine administration. Used as the canonical NMDA glycine-site co-agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-374Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-374

D-Serine

Abstract

Read the full monograph